The clinical pharmacology of biotechnology products : proceedings of the Esteve Foundation Symposium IV, Son Vida, Mallorca, 7-10 October 1990
著者
書誌事項
The clinical pharmacology of biotechnology products : proceedings of the Esteve Foundation Symposium IV, Son Vida, Mallorca, 7-10 October 1990
（International congress series, no. 944）（Esteve Foundation symposia, vol. 4）
Excerpta Medica , Sole distributors for the USA and Canada, Elsevier Science Pub. Co., 1991
大学図書館所蔵 件 / 全6件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes indexes
内容説明・目次
内容説明
Researchers in new biology, clinical pharmacologists, physicians, and administrators have bundled their knowledge to produce this enlightening book, covering a broad range of subjects, contributing to helping new biology, through biotechnology, achieve its potential of improving the health of all people everywhere. First, the book takes a general look at biotechnology as a source of drugs. Next is discussed the disposition and pharmacokinetics of peptides and proteins since these differ from the disposition and kinetics of small organic molecules, the traditional types of drugs. Assessing the safety of biotechnology products, and the safety assessment of small organic molecules is also a topic covered by the book, as well as an overview of some of the ways the products of the new biology will have an impact, financially and otherwise, on society.
目次
Biotechnology as a source of drugs. Purification of proteins: Converting a culture broth into a medicine (R.G. Werner). Discussion. Human insulin and its modifications (J.A. Galloway, R.E. Chance and K.S.E. Su). Discussion. The use of recombinant proteins in AIDS research: Development of a CD4/gp120 binding assay (J. Mous, C. Manzoni and L. Dirckx). Discussion. FGF receptors as targets for drug development (C.A. Dionne, M. Jaye and J. Schlessinger). Discussion. Development of antagonists for IFN and TNF (M. Steinmetz). Discussion. Proteins in search of a disease (L. Gauci). Discussion. Pharmacokinetics of biotechnology products. Absorption of therapeutic peptides (B.R. Meyer). Discussion. Pharmacokinetics of human tissue-type plasminogen activator (P. Tanswell, E. Seifried and J. Krause). Discussion. Role of the kidney in eliminating proteins and peptides (D.C. Brater). Discussion. Evaluation of biotechnology products. Possible problems associated with cytokine contamination of biotechnology products (A. Gearing, M. Wadhwa and R. Thorpe). Discussion. Selection of animal species and length of toxicity studies with recombinant proteins. Review of industry and regulators' approach and case history of rec-hirudin (P. Graepel, F. Pfannkuch and R. Hess). Discussion. Toxicological development of hematopoietic growth factors (H. Ronneberger). Discussion. Meaningful evaluation of biotechnology products (P. Juul). Discussion. Pharmacologic and therapeutic actions of biotechnology products. Biological and clinical response of recombinant interferon gamma in patients with advanced renal cell cancer (W. Aulitzky, G. Gastl, W.E. Aulitzky, J. Frick and C. Huber). Discussion. Tissue-type plasminogen activator (H.R. Lijnen and D. Collen). Discussion. Erythropoietin (F. Valderrabano). Clinical pharmacology of hirudin (HBW 023) (H.-J. Roethig, J.S. Maree and B.H. Meyer). Discussion. Therapeutic actions of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) (A. Ganser and D. Hoelzer). Discussion. Potential use of peptide hormones in sport (J. Segura, R. de la Torre and R. Badia). Discussion. Biotechnology and society. Costs of discovering, developing, manufacturing and marketing biotechnology products (W.M. Wardell). Discussion. The impact of economic issues on the therapeutic usage of biotechnology products. A view from the hospital (M. Levy and S. Penchas). Discussion. Biotechnological products, can this commodity be afforded? (F. Garcia-Alonso). Discussion. Concluding remarks (M.M. Reidenberg). Index of authors. Keyword index.
「Nielsen BookData」 より